From Jab to Pills: Novo Nordisk, Eli Lilly set to take obesity drug battle to India

India’s obesity drug market is set for a new phase as Novo Nordisk’s oral Wegovy and Eli Lilly’s oral GLP-1 orforglipron are expected to launch in the first half of 2027. Industry sources said both have been submitted to Indian regulators, potentially expanding demand beyond injectable treatments.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CkebFWv
via IFTTT

Read More

Lord’s Mark secures MHRA registration for dialysis device, plans UK expansion

Lord's Mark Industries Limited has successfully secured regulatory registration from the MHRA for its innovative haemodialysis machine, paving the way for its expansion in the UK's healthcare technology sector. With plans to commence exports in January 2027 and potentially establish its own dialysis centres, this milestone signifies a crucial step towards creating a comprehensive renal-care ecosystem, manufactured by Renalyx Health Systems Pvt. Ltd. for both institutional and home usage.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yfeC9vG
via IFTTT

Read More

ChrysCapital to take minority stake in Linux laboratories

Linux Laboratories has secured $70 million in equity funding from ChrysCapital and Tata Capital Healthcare Fund III. This investment involves both primary capital and a secondary purchase, marking Tata Capital Healthcare Fund II's full exit. The funding will help Linux deepen its presence in existing specialties and expand into new therapeutic areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RybAXgJ
via IFTTT

Read More

Sun Pharma plans $1 billion local debt sale for loan takeout, sources say

Sun Pharma is planning to raise about Rs 10,000 crore through rupee-denominated bonds to partly refinance a bridge loan used for its Organon acquisition, according to Reuters. The drugmaker is expected to issue two-, three- and four-year bonds as Indian companies increasingly turn to domestic debt amid high US borrowing costs and expectations of an RBI rate hike.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8rh4Cyg
via IFTTT

Read More

SC draws the line on Fortis audit, says no ‘fishing and roving’ probe into banks

The Supreme Court clarified the forensic audit's focus is on Fortis Healthcare Holdings Private Limited and the Singh Brothers. This audit is not a broad inquiry into the dealings of other banks. The court highlighted the audit relates specifically to transactions between FHHPL, FHL, and banks involved. The clarification came in response to a prior ruling by the Delhi High Court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eLn10bd
via IFTTT

Read More

Kerala HC says exorbitant drug prices can trigger government intervention in patented medicines

The Kerala High Court ruled that government intervention is permissible for prohibitively priced patented medicines. The court directed the Centre to gather data on the affordability of specific life-saving drugs. This ruling addresses access issues for two breast cancer medications, abemaciclib and ribociclib. The decision empowers the government to consider invoking Section 100 of the Patents Act for affordable access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kNIEnjZ
via IFTTT

Read More

Sun Pharma signs major deal with LIB Therapeutics of US, gains access to $3.7-bn global market for bad cholesterol inhibitor PCSK9

Sun Pharma has signed an exclusive agreement with LIB Therapeutics for Lerodalcibep, a cholesterol-lowering medication. This deal covers all markets globally except for the United States and China. Lerodalcibep, a once-monthly PCSK9 inhibitor, will be marketed under the name Lyrokaul in Europe.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YrEHkSp
via IFTTT

Read More

Govt, private hospitals likely to be graded on quality & safety

Niti Aayog is developing a national quality framework for public and private hospitals, aligned with international standards, to help patients compare hospitals and improve healthcare quality. The framework will include patient safety, clinical outcomes, readmission rates, medication errors and specialty-specific indicators such as survival and mortality rates.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dRmPYG1
via IFTTT

Read More

CDSCO steps up scrutiny of pharma drugs containing narcotic substances

The Central Drugs Standard Control Organisation is addressing regulatory gaps related to the illegal diversion of pharmaceutical drugs. Following the National Committee for Coordination on Drug Trafficking meeting, specific targets have been assigned to CDSCO. The drugs consultative committee will examine current regulations to recommend improvements. Union home minister Amit Shah emphasized the need for a coordinated strategy against evolving drug trafficking.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y3KmoGR
via IFTTT

Read More

Fortis Healthcare confident forensic audit will clear company in share transfer dispute

Fortis Healthcare has expressed confidence that a forensic audit will verify its non-involvement in a share transfer dispute. The Supreme Court's recent ruling allows the audit to proceed while minimizing the influence of previous judgments. Fortis clarified that it was never a party to the arbitration between the Singh Brothers and Daiichi Sankyo.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oL67Mlu
via IFTTT

Read More

Fortis defends itself after Supreme Court allows forensic audit, says it was "complete stranger" to Daiichi-Singh Brothers dispute

In a disclosure to the stock exchanges, Fortis said the Supreme Court, in its September 25 order, disposed of the company's Special Leave Petition challenging the Delhi High Court's August 31 order directing a forensic audit of the company in the matter of Daiichi Sankyo Company Limited vs. Malvinder Mohan Singh & Ors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kF1jaJZ
via IFTTT

Read More

Ayush services sector growing fast; projected to hit up to USD 318 billion by 2047: Study

The Ayush services sector is projected to reach USD 216-318 billion by 2047 as it continues to expand. This sector reported a 16.91 percent compound annual growth rate since 2022-23 and supported 1.76 million livelihoods. Clinics and day-care centers generated the majority of the sector's revenue, with Ayurveda leading individual systems. The sector's role in Medical Value Travel is also notable with international patients contributing substantially to revenues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/30xLvPX
via IFTTT

Read More

India needs five-year policy to make precision cancer care afforable, says expert

India needs a five-year roadmap to expand access to genomic testing and targeted cancer therapies for lower-income patients, oncologist Dr Bhawna Sirohi said. A member of the new Lancet Oncology Commission on precision cancer, Sirohi flagged high testing and drug costs and urged their integration into public healthcare schemes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dw9NSF2
via IFTTT

Read More

Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India

Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, despite their India sales accounting for less than 0.5% of global revenues. Court submissions have highlighted development, clinical-trial and manufacturing costs against the medicines’ prices in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yJxf8Zh
via IFTTT

Read More

SC clears forensic audit of Fortis-IHH deal involving erstwhile Religare promoters Singh brothers

The Supreme Court has cleared the way for a Delhi High Court-appointed forensic auditor to examine transactions involving Fortis Healthcare, Malaysia’s IHH Healthcare and entities linked to former promoters Malvinder and Shivinder Singh. The audit will trace assets linked to the brothers and examine the dilution of their Fortis shareholding.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8TvcrQx
via IFTTT

Read More

Supreme Court backs Delhi HC orders in Daiichi-Fortis dispute, clears way for forensic audit

The Supreme Court has declined to interfere with Delhi High Court orders in the long-running Daiichi Sankyo-Fortis dispute, allowing a forensic audit to proceed as part of efforts to trace assets linked to enforcement of a 2016 arbitral award against former Fortis promoters. The apex court did not examine the merits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MsfkSCY
via IFTTT

Read More

Alkem Laboratories CFO Nitin Agrawal resigns

Alkem Laboratories CFO and Key Managerial Personnel Nitin Agrawal has resigned from the drug maker to pursue new professional opportunities, the company said in a regulatory filing. Agrawal will step down from his senior management position effective September 30, 2026. He cited long-term professional and personal growth in his resignation letter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WQ9gku1
via IFTTT

Read More

HLL Lifecare to expand pharmacy network to 600 outlets, add 4,500 jobs

HLL Lifecare Ltd intends to broaden its pharmacy network to 600 outlets nationwide over the coming year, creating around 4,500 job opportunities in healthcare. With around 340 existing stores, HLL champions affordable healthcare solutions while ensuring vital services reach all citizens. Notably, this expansion will roll out just in time for World Pharmacists Day on September 25.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QnXliu9
via IFTTT

Read More

Goldman Sachs picks up stake in Lord’s Mark Industries Limited

Lord’s Mark Industries Limited has garnered impressive interest from investors following the sale of approximately 1 crore shares by its promoter. This strategic move was intended to meet SEBI’s Minimum Public Shareholding norms, boosting the company’s visibility in the market. Prominent investors like Goldman Sachs Investments Mauritius I and AT Trade Overseas took part in this endeavor.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PLw2EHT
via IFTTT

Read More

Zydus Lifesciences expects decent growth for five years as innovation matures: Sharvil Patel

Zydus Lifesciences is transitioning from a traditional pharmaceutical company to a more patient-driven organization. The company plans to focus on specialty medicines and biotechnology innovation. It aims to achieve double-digit revenue growth and improved profitability over the next five years. Zydus intends to enhance its oncology franchise and explore partnerships for novel biologics. The expected contributions from discovery-led products will materialize from 2030 onwards, strengthening its market position.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NYwr5pR
via IFTTT

Read More

Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD

"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business and Saroglitazar and maybe something more as well. In the next four to five years we will definitely see meaningful value being created from these."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e0dODfu
via IFTTT

Read More

How India’s smaller hospitals are becoming the next big digital health market

Smaller hospitals in India are becoming the new digital health market. As the Ayushman Bharat Digital Mission expands, the demand for digital solutions had increased. Healthcare tech companies are focusing on providing solutions tailored to smaller providers. Despite challenges in implementation, the integration into existing workflows could improve patient experiences significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Uz3Gadq
via IFTTT

Read More

Pfizer India speaks up after Karnataka FDA crackdown, says patient safety is top priority

Pfizer India has stated that patient safety and product quality are their top priorities following FDA actions. The Karnataka FDA canceled 16 drug licenses and suspended eight others due to counterfeit drugs. A raid uncovered an illegal operation repacking low-cost medicines as branded drugs, particularly Pfizer products. Pfizer has removed affected batches from the market and is cooperating with authorities in the investigation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/owXUsIV
via IFTTT

Read More

Ozempic maker Novo Nordisk sets sights on hair-loss market

The condition is part of a list of areas, including addiction and menopause, where Novo sees potential overlap with either its core scientific expertise or the skills it's recently built in selling prescription drugs directly to consumers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A7nF6lZ
via IFTTT

Read More

Root of the matter: What to know before trying professional hair treatments

Professional hair treatments can deliver smoother, shinier and more manageable hair, but their effects and risks vary depending on the treatment, formulation and existing hair health. This article explains how treatments such as keratin, relaxers and hair botox work, key questions to ask before a salon treatment, potential risks and why maintaining overall hair and scalp health matters beyond cosmetic results.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YEZ4asr
via IFTTT

Read More

Bharat Biotech is 'back in action' after Covid reset: Krishna Ella on TB vaccine, Nipah-Ebola shots, gene therapy, IPO plans & what’s next

Bharat Biotech is “back in action” after a two-year post-Covid reset, founder Krishna Ella says, with the company expanding beyond vaccines into cell and gene therapy and monoclonal antibodies. The vaccine maker is advancing programmes for TB, Nipah, Ebola, chikungunya, malaria, Zika and antimicrobial resistance, while exploring an IPO to fund new therapies and potential acquisitions. Ella says the company, which currently has around Rs 2,000 crore in revenue and is debt-free, is focused on accelerating innovation and preparing the next generation to lead its human and veterinary businesses.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/py9TwbP
via IFTTT

Read More

Medical device rules may get tougher: Govt plans new powers to stop manufacture, sale of unsafe, defective and spurious products, order destruction

The government is considering tougher medical device rules that could give regulators explicit powers to stop the manufacture, sale or distribution of unsafe, defective, substandard or spurious products and order their destruction. The proposed amendment to Rule 30(1) of the Medical Devices Rules, 2017, is aimed at strengthening enforcement, reducing ambiguity and ensuring potentially harmful devices are removed from circulation more quickly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4ONHaMD
via IFTTT

Read More

Ichor Biologics seeks $80-100 million PE funding for minority stake sale

Ichor Biologics is seeking eighty to one hundred million dollars from private equity investors. The Hyderabad-based company operates in the specialized plasmatherapy segment. Promoters Ananda Reddy Sudini and Sujana Sudini hold significant stakes in the firm. Ichor manufactures therapeutic protein products derived from human plasma. The company's products serve various critical therapeutic areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dLQtXB1
via IFTTT

Read More

Unify Group marks ten years of success with The Grand Gala

Celebrating a decade of excellence, Unify Group hosted an impressive gala event that showcased its remarkable journey since its inception in 2016. Initially rooted in healthcare, the organization has boldly ventured into travel, logistics, and technology, paving the way for future innovations. The evening was a tribute to their significant milestones and a look ahead at the blossoming opportunities in their expanding portfolio.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XlzQewb
via IFTTT

Read More

Biocon arm gets positive EMA panel recommendation for breast cancerbiosimilar Pebrilzo

Biocon Biologics has received a positive recommendation from the European Medicines Agency’s CHMP for its Pertuzumab biosimilar, Pebrilzo, for HER2-positive breast cancer. The European Commission will take the final decision on marketing authorisation across the EU.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8XivGI1
via IFTTT

Read More

Aragen steps up investment in complex drug modalities; plans 500 KL new CDMO capacity

Aragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-molecule CDMO capacity and a biologics facility. Aragen aims to transition from a molecules company to a medicines company through expansion. This strategic move aligns with global drugmakers seeking supply chain alternatives outside China. The firm is also developing its own intellectual property around antibody-drug conjugates.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LxkSpVN
via IFTTT

Read More

Karnataka medical institute opened by PM plans free cancer immunotherapy for patients

The Sri Madhusudan Sai Institute plans to offer free immunotherapy for cancer patients. A new 600-bed hospital will soon launch on campus, expanding free medical services. Modern genomics treatment is already initiated, and rare disease research is underway. The mission has invested significantly in service initiatives and seeks corporate and international support. Free paediatric healthcare and nutrition programs are also highlighted as key achievements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jH0WehJ
via IFTTT

Read More

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger scientific evidence and safety monitoring for wider adoption. The Central Council for Research in Ayurvedic Sciences stressed this at a symposium. Discussions focused on safety and evidence-based care for non-communicable diseases. The council highlighted its work in public health and traditional medicine. Strengthening pharmacovigilance is crucial for patient safety in Ayurveda.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BYGD7aX
via IFTTT

Read More

ENTOD Pharmaceuticals secures patent for its insulin eye drop

Currently at the pre-clinical stage of development, the patented insulin eye drops are being investigated as a potential novel therapeutic approach to address unmet needs in ophthalmic care, the Mumbai-based company said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IVdDPMv
via IFTTT

Read More

When doctor is at home: Technology enables 24x7 monitoring beyond hospital

A new technology offers continuous remote health monitoring for patients at home. This system helps individuals recovering from surgery and the elderly stay supervised. Patients receive regular check-ins and immediate advice for any health abnormalities. The technology uses biosensors to track vital signs and prevent emergencies. This innovation provides reassurance and timely medical support for many individuals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PyEDvtO
via IFTTT

Read More

Drugs Panel to weigh bringing all sterile drug products under central licensing amid contamination concerns

A proposal will soon be considered to centralize licensing for all sterile drug products. This move aims to tighten regulations on medicines prone to microbial contamination. Currently, only specific sterile medicines fall under central licensing authority. The proposal highlights fragmented existing frameworks and varying state inspection practices. Bringing all sterile products under central oversight will create a uniform regulatory system.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/nUrDiCs
via IFTTT

Read More

QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it

India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. Takeda will retain rights for public market distribution as a future objective. QDENGA is a two-dose vaccine designed to protect against all four dengue virus serotypes. Dengue cases have significantly increased in India over the past two decades.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dGtOv2Z
via IFTTT

Read More

Health ministry issues advisory against unregulated stem cell therapies, restricts autism treatment to approved clinical trials

The Union health ministry issued an advisory against unregulated stem cell therapies. Therapeutic use of stem cells for autism is restricted to approved clinical trials. This advisory reiterates the existing framework governing stem cell research and therapy. It aligns with a Supreme Court ruling restricting unproven stem cell treatments. States and union territories must ensure strict compliance with the applicable framework.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/invwzoN
via IFTTT

Read More

Can wearable tech ease period pain? Curapod launches new device

Curapod has launched a new wearable device for menstrual pain management. This device utilizes red and near-infrared light wavelengths for pain relief. The wearable connects to a mobile application for personalized light dosage adjustments. Clinical evaluations indicate significant pain reduction for many users. The company is expanding its wearable technology into other pain management areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZYaf8nh
via IFTTT

Read More

Centre seeks NPPA report on high markups in hospital consumables

The Centre has requested a report from the NPPA regarding price discrepancies. Maharashtra FDA flagged significant gaps between trade prices and MRPs for hospital items. A survey revealed markups of over 2,800 percent on certain medical consumables. This situation may revive discussions on trade margin rationalisation for medical devices. The medical device industry supports calls for fair pricing and ethical practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tIavsxu
via IFTTT

Read More

US names India, China, Pakistan among drug transit, illicit drug-producing nations for FY27

The United States has designated India, China, and Pakistan as major drug producing or transit countries. This presidential determination covers twenty-three nations for fiscal year twenty twenty-seven. Afghanistan, Bolivia, Burma, and Colombia were separately identified for failing counternarcotics obligations. Inclusion on the list considers geographic and economic factors for drug production and transport. This designation does not necessarily reflect current government efforts or US cooperation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UOjoGXe
via IFTTT

Read More

Dr. Reddy's launches nivolumab biosimilar in India

Dr Reddy's Laboratories has taken a significant step in cancer care with the introduction of NIVORZ, a biosimilar of nivolumab. Designed to enhance immune response against a variety of cancers, this new treatment has received approval from the DCGI for twelve specific indications. By making this intravenous therapy available, Dr Reddy's aims to broaden access to affordable, high-quality cancer care options for patients in need.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T2NwOSC
via IFTTT

Read More

Centre proposes easier norms for faster drug rollout

India's government plans to streamline drug approval processes for domestic use. Applicants can now start studies after intimating the drug regulator. Import license processing timelines for new drugs will be halved to forty-five days. This move aims to improve the ease of doing business in the sector. However, certain high-risk drug categories will retain existing stringent requirements.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cMTsGlP
via IFTTT

Read More

New TB vaccines expected from 2029 could prevent 7.3 million deaths by 2050, Gavi says

By 2029, new tuberculosis vaccines are expected to save more than seven million lives, emerging as a crucial element for global health improvement. Ensuring a steady supply for the countries most affected by the disease is essential. Additionally, these vaccines may provide considerable economic advantages for developing nations. Gavi aims to promote timely accessibility and widespread distribution of these immunizations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y8JHTRa
via IFTTT

Read More

Ayurveda eyes global growth as research, innovation reshape traditional system

Ayurveda is gaining global relevance through research and innovation. Growing interest in holistic healthcare creates new international opportunities for this system. India's Ayush market has seen significant economic growth in recent years. The government promotes Ayush-based medical travel and introduced a dedicated visa. Ayurveda's future international success depends on evidence and standardized practices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/irgcVF9
via IFTTT

Read More

Manipal Hospitals scouts for acquisitions in Andhra, Keralam, Delhi-NCR; bets on AI-led healthcare

Manipal Health Enterprises plans significant expansion across several Indian states. The company is adopting a digital-physical healthcare model driven by Artificial Intelligence. Strategic acquisitions and a new greenfield project in Mumbai are underway. Investments focus on AI-enabled nursing and patient monitoring systems. The healthcare major aims to add over 2,400 beds by the year 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ALijwlZ
via IFTTT

Read More

AstraZeneca's breast cancer drug fails in late-stage trial

AstraZeneca's breast cancer drug Etcamah did not meet its main goal in a late-stage trial. The drug showed only a numerical improvement when combined with palbociclib. This marks a setback for the recently approved treatment, which received accelerated approval. U.S.-listed shares of AstraZeneca experienced a decline in aftermarket trading. Trial data will be shared by the company in due course.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mdZjpwy
via IFTTT

Read More

Imported dialysis solution fails endotoxin test in Himachal; lab flags nine regulatory violations

A Himachal Pradesh government drug laboratory has declared two batches of an imported peritoneal dialysis solution “Not of Standard Quality” after they failed bacterial endotoxin tests. The report also flagged nine regulatory violations, including use of non-Indian pharmacopoeial standards, labelling deficiencies, missing safety warnings and inadequate importer details.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fbDLdI7
via IFTTT

Read More

Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility with nil observations

Alembic Pharmaceuticals has reported that its Vadodara facility passed the recent inspection by the United States Food and Drug Administration with flying colors. Conducted from August 31 to September 10, 2026, the inspection resulted in zero observations, leading to a clean report from the USFDA and highlighting the facility's commitment to excellence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/a6w7jzn
via IFTTT

Read More

India crosses 80 lakh HPV vaccinations in nationwide cervical cancer prevention drive

India has now administered over 80 lakh HPV vaccinations to girls. This significant milestone strengthens preventive healthcare and protection against HPV infection. The nationwide campaign, launched in February, targets fourteen-year-old girls for free vaccination. The Gardasil-4 vaccine is available at government health facilities across the country. Parental consent is mandatory for this voluntary immunization program.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FGjfMd7
via IFTTT

Read More

Marengo Asia Hospitals raises Rs 400 crore from LeapFrog Investments

Marengo Asia Hospitals has secured Rs. 400 crore funding from LeapFrog Investments. This capital will fuel expansion into tier one and two Indian cities. The company plans to double its hospital bed capacity to 4,000 beds. Marengo Asia Hospitals aims to consolidate its leadership and enter new geographies. This investment reinforces LeapFrog's commitment to healthcare platforms across Asia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HnosAqO
via IFTTT

Read More

iKure bags USD 1.8 Million from global investors to expand primary healthcare in India

iKure Techsoft has successfully raised USD 1.8 million in Pre-Series A funding. This infusion of capital is set to bolster its frontline healthcare workforce and enhance infrastructure, while also advancing its digital health platform through AI integration. iKure aims to provide ongoing care to patients, ensuring access to vital healthcare services for underserved communities across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9XYpLUM
via IFTTT

Read More

Regional healthcare hubs emerge as new investment hotspots

Investment is shifting to regional hospital hubs like Jaipur and Vadodara. These markets offer growth opportunities and lower operating costs for investors. Health insurance penetration is also increasing significantly in these areas. Single-specialty segments like IVF and mother-child care are driving deal activity. Regional hospital brands are expected to scale through clusters and strengthen networks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Dr5QALi
via IFTTT

Read More

WHO chief meets JP Nadda, praises India's health gains in maternal, child care and TB fight

WHO chief Tedros Adhanom Ghebreyesus praised India's health sector progress. He highlighted advancements in maternal and child health initiatives. India's Ayushman Arogya Mandirs bring health screenings closer to communities. ASHA workers support mothers and children from conception through adolescence. Discussions also covered India's efforts to end tuberculosis and strengthen regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xF7adih
via IFTTT

Read More

Sun Pharma incorporates global treasury arm at IFSC, GIFT City

On September 8, 2026, Sun Pharmaceutical Industries Ltd announced the establishment of its new subsidiary, Sun Pharma Global Treasury Centre IFSC Ltd. Located in Gujarat's GIFT City, Gandhinagar, this wholly-owned indirect unit has seen an investment of around Rs 9.50 crore in its equity share capital. The company is currently awaiting necessary approvals from the International Financial Services Centres Authority to commence its operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ENqUfp3
via IFTTT

Read More

Tylenol use in pregnancy may be linked with uterus, ovary changes in daughters

A recent study suggests Tylenol use by mothers during pregnancy may affect infant reproductive organ development. Researchers observed smaller ovaries and uteruses in three-month-old girls exposed to the drug. This exposure was also linked to fewer ovarian follicles and lower reproductive hormone levels. Long-term follow-up is needed to determine implications for future fertility and menopause timing. Current guidelines still recommend Tylenol as safe for pregnancy pain and fever relief.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RqiEfv6
via IFTTT

Read More

Government panel plans to retain rule allowing doorstep drug delivery

A government sub-committee has decided to uphold the 2020 rule for doorstep delivery of medicines, recognizing its critical importance for elderly patients and those living in remote locations. Despite the chemists' request to revoke the rule due to concerns of misuse by digital platforms, the sub-committee concluded that maintaining this service is essential for vulnerable populations, recommending instead a stricter enforcement of the existing regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jzdx9C8
via IFTTT

Read More

Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid

Rating agencies Moody's and S&P assigned investment-grade ratings to Sun Pharmaceutical Industries. This action follows Sun Pharma's proposed acquisition of US-based Organon & Co. The deal is expected to significantly bolster Sun Pharma's business position and revenue base. Organon will contribute substantially to the group's earnings after the acquisition. This strategic move will enhance Sun Pharma's scale and geographic reach.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mpojfhz
via IFTTT

Read More

Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drug

In a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its collaboration with Bahiafarma and Bionovis. This partnership offers exclusive rights to supply the public healthcare sector in Brazil, with plans for phased localization of production. This endeavor aims to improve accessibility to critical cancer therapies while fostering local industry growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/75cGBLe
via IFTTT

Read More

Centre may provide 100% funding support for medical testing equipment, says Piyush Goyal

The government will fully fund the acquisition of advanced medical testing equipment. Domestic firms are encouraged to seek technology partnerships and joint ventures. India aims to become a global hub for medical innovation and device development. Hospitals must offer transparent treatment packages and ethical patient care practices. Enhancing interpreter services will improve foreign patient confidence and communication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zIGLUJt
via IFTTT

Read More

Novartis India to acquire Pfizer's 'Minipress' trademark for Rs 1,250 crore

Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore. Minipress XL, used for hypertension and benign prostatic hyperplasia, generated ₹228.6 crore in revenue as of July 2026, according to IQVIA data.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TNo8DCW
via IFTTT

Read More

'No fake Abhayrab vaccine exported': Indian Immunologicals clarifies after Delhi Police seize counterfeit rabies vaccine batch

Indian Immunologicals confirmed no counterfeit Abhayrab vaccine batch was exported. Four individuals were arrested by Delhi Police after seizing fake vaccine vials. The manufacturer stated all vaccine batches undergo independent testing and government certification. This ensures vaccines reach patients through regulated and authorized supply chains. Previous counterfeit batches had triggered international health authority alerts for travelers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/njKqvM9
via IFTTT

Read More

Pharma sector must attract more investment in clinical trials, R&D: Piyush Goyal

Piyush Goyal emphasized the importance of enhancing India's pharmaceutical industry to draw in more investments. He urged for the creation of robust supply chains to avoid reliance on a single country. The minister also championed the idea of bolstering research and development, securing patents for Indian innovations, and promoting alignment with global regulatory standards. Furthermore, he recommended increasing production in the Ayush sector and medical devices to achieve global recognition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uSMw7cZ
via IFTTT

Read More

Growing peptide trend raises safety concerns among doctors

Doctors express concern over popular injectable peptides for various health benefits. They caution that established peptide medicines differ from experimental compounds promoted online. Social media influencers and wellness trends encourage experimentation with unapproved injectable peptides. Experts emphasize that "peptide" is a chemical category, not a safety guarantee.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VH5JXIE
via IFTTT

Read More

RPG Life Sciences to deploy Rs 500 crore in next 12 months to bolster manufacturing, API capabilities

RPG Life Sciences plans to deploy Rs 500 crore over the next 12 months to expand manufacturing and API capabilities through strategic acquisitions, Managing Director Ashok Nair said. The drugmaker has committed Rs 700 crore for expansion and targets Rs 2,000-2,500 crore revenue by 2030, supported by domestic and international growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JQC9k2U
via IFTTT

Read More

Novartis India to pursue therapy-aligned acquisitions; eyes expansion in Tier 2 and Tier 3 markets

Novartis India plans acquisitions and deeper market penetration for future growth. The company will focus on five key therapy areas for expansion. Established brands will be brought under full commercial control by 2026-27. Rising chronic diseases and an aging population drive sustained therapy demand. Improved insurance and healthcare infrastructure will unlock new patient demand.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lN0ugx3
via IFTTT

Read More

Seized Abhayrab vials not manufactured by company: Indian Immunologicals Limited

Indian Immunologicals Limited has asserted that the rabies vaccine vials in question were not produced by their facility. Following a potency test failure, a batch was labeled substandard by the drug regulator. IIL emphasized that the Central Drugs Laboratory in Kasauli had assessed and approved the batch. The company identified seventeen discrepancies between the seized vials and their retention samples.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LFCcRA5
via IFTTT

Read More

Govt flags Abhayrab rabies vaccine batch as substandard, probes if spurious, document shows

India's drug regulator has flagged a batch of Abhayrab rabies vaccine as substandard. This finding marks the second time concerns have been raised about counterfeit Abhayrab doses. The government's Central Drugs Laboratory found the vaccine did not meet potency requirements. Significant differences were noted between the sampled product and a reference sample. The regulator is investigating whether the vaccine is spurious under Indian law.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WJKZFAz
via IFTTT

Read More

Moopen family picks up additional stake in Aster DM Quality Care for Rs 350 cr

Union (Mauritius) Holdings acquired a 0.57 percent stake for Rs 350.34 crore. This acquisition increased the Moopen family's total shareholding to approximately 24.58 percent. The transaction involved purchasing equity shares from Centella Mauritius Holdings Ltd. The deal was executed at a price of Rs 760 per share on September 2. Aster DM Quality Care now operates a network of 39 hospitals across 28 cities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j6mh1zy
via IFTTT

Read More

Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar

Cipla said its US unit has entered an exclusive partnership with China’s Qilu Pharmaceutical to license QL2107, a biosimilar of Merck’s cancer drug Keytruda. Qilu will handle development, approvals, manufacturing and supply, while Cipla USA will commercialise the treatment in the US, as Cipla expands its oncology biosimilars portfolio.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/TJnt7ON
via IFTTT

Read More

Drug cos refuse to take sole responsibility for overpricing

Indian drugmakers oppose a proposal making them solely liable for medicine overpricing. This regulatory move exempts retail chemists, hospitals, and nursing homes from penalties. Pharmaceutical groups argue this unfairly burdens manufacturers already following pricing rules. Retail chemists, however, welcome the safeguards for their members. Manufacturers believe accountability should extend to those setting the final patient price.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A9slboD
via IFTTT

Read More

Cohance Lifesciences to invest USD 18 mn in NJ Bio, Aruka Bio

Cohance Lifesciences announced an eighteen million dollar investment to strengthen its antibody-drug conjugate strategy. This includes thirteen million dollars for NJ Bio, increasing Cohance's ownership to sixty-seven point three percent. An additional five million dollars will give Cohance a sixty-five percent stake in Aruka Bio. These transactions aim to integrate NJ Bio's services with Cohance's manufacturing capabilities. Completion of these strategic investments is expected by September twenty twenty-six.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j7mLd9n
via IFTTT

Read More

Max Healthcare to invest Rs 6,200 cr to reach 10,000-bed capacity in 3 years: CMD

Max Healthcare plans to expand its bed capacity to ten thousand beds. This significant expansion will involve an investment of approximately six thousand two hundred crore rupees. The company's growth is driven by increasing domestic demand and India's medical tourism prominence. Medical tourism currently represents nine percent of the company's overall business operations. This strategic move aims to address the growing healthcare needs across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4a5D6lo
via IFTTT

Read More

RPG Life Sciences subsidiary acquires Raghava Life Sciences' API biz for Rs 135 cr

RPG Active Pharma is acquiring Raghava Life Sciences' API and intermediates business. This strategic move aims to strengthen its integrated API play and manufacturing footprint. The acquisition includes twenty-two commercialized APIs and seven development-stage assets. This transaction will be executed on a going-concern basis through a slump sale.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OgsZw8E
via IFTTT

Read More

Monsoon illnesses & flu surge lift drug demand

Monsoon illnesses and a significant rise in H1N1 cases are driving a surge in demand for acute therapies and flu vaccines. Sales of anti-infectives and antibacterials saw a 12% month-on-month increase in July, with flu vaccine sales nearly tripling year-on-year in August, leading to supply challenges in several cities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ak4YGcN
via IFTTT

Read More

Sun Pharma agrees to lower US drug prices under Trump plan; analysts see limited financial impact

Sun Pharmaceutical Industries will offer its drugs at prices matching other developed nations. This agreement aims to make healthcare affordable for low-income Americans. Analysts believe the financial impact on Sun Pharma will be minimal. The company's US revenue contribution is significant, reinforcing its growth strategy. This pact recognizes Sun Pharma's investment in the American market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/72ErY3T
via IFTTT

Read More

Permira to buy 25.71% in Cloudnine Hospitals parent: CCI filing

Permira, a leading global private equity firm, is ready to buy a significant stake in Cloudnine Hospitals, which places the parent company's valuation at approximately eleven thousand crore rupees. This acquisition involves purchasing the stake from existing investor True North Capital. The deal awaits appropriate regulatory clearances, and Cloudnine is also exploring acquisitions of further hospital ventures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gIk8GKT
via IFTTT

Read More